July 2026 Research Update

This month, studies in ATTR cardiac amyloidosis focused on better ways to measure day-to-day heart function and track change over time, rather than on new drugs. One approach grouped people by patterns seen during an exercise breathing test and lined up well with walking distance and symptom class, which helps describe different functional profiles. Another approach used a more quantitative form of bone-tracer heart imaging and reported that the measured heart signal fell after tafamidis, raising the possibility of tracking change with a number rather than only visual grades. [1] [2]

In the exercise testing study, people in worse RoMa classes had shorter 6-minute walk distances and more limitations by NYHA symptom class, and the exercise test numbers also looked worse across classes. In plain language, the classification appeared to separate patients who could do more activity from those who were more limited, using measurements taken during exercise. This matters because a consistent way to describe functional differences could make it easier to compare patients in research and potentially follow progression, but this work was presented as exploratory. [1]

In the imaging study of 25 people with wild-type ATTR-CM, the measured uptake values in the heart on SPECT/CT (SUV-style numbers) dropped after tafamidis, while a bone reference value stayed stable. The study also reported that a baseline imaging number (SUVpeak) tracked with the usual visual Perugini score, suggesting the new numbers relate to established grading. For patients, the practical idea being tested is whether imaging can show a change over time in a way that is easier to quantify, although the study did not report how these imaging changes related to symptoms or long-term outcomes. [2]

These studies mainly add to how ATTR-CM might be measured and followed in research, and they do not by themselves show that a person will feel better or live longer based on a test result. In the nearer term, they help explain why different clinics and studies may use exercise capacity and imaging in more structured, numerical ways to describe ATTR-CM severity or change. What remains uncertain is how well these newer measurements predict individual prognosis, and whether changes in these numbers reliably match changes in symptoms for a given person. [1] [2]

This month included several case reports showing how wild-type ATTR cardiac amyloidosis can overlap with other heart problems and how care can become very individualized. Across cases, the common message was not that one strategy works for everyone, but that wtATTR-CM often appears alongside valve disease, rhythm problems, and fluid overload, creating situations where standard tests or standard procedural approaches may not be straightforward. Because these are single-patient stories, they are best read as examples of what can happen rather than as proof of benefit. [3] [4] [5] [6] [7]

One report described wtATTR-CM with heart failure where a pulmonary artery pressure sensor was used to guide management alongside transthyretin-stabilizing therapy, and pressures fell over 3.5 years while diuretic dose was reduced. In plain language, this single case suggests that remote pressure tracking can be paired with ATTR therapy and may coincide with hemodynamic stability, but it cannot show which part of the approach drove the changes. For patients, it highlights a monitoring option sometimes used in difficult-to-manage heart failure, but evidence in ATTR-CM remains very limited in the provided report. [3]

Two reports centered on valve disease in people with wtATTR-CM, showing how anatomy and low-flow states can complicate decisions and procedures. In one person with low-flow, low-gradient aortic stenosis plus wtATTR-CM, common tests still did not clearly label the valve narrowing as truly severe, yet TAVI was performed and the person later had improved heart pumping function and sustained clinical improvement during follow-up, with tafamidis started shortly after. In another person with severe tricuspid valve leakage, a transfemoral repair attempt failed because of an anatomic structure, but switching to a neck-vein approach allowed clip placement and reduced leakage to mild. [4] [6]

Two additional cases focused on disease course and diagnosis rather than procedures. One person with wtATTR-related heart involvement and reduced ejection fraction improved on conventional heart failure medications for a time, but later developed atrial fibrillation, worsening heart failure, and ultimately died, with tafamidis planned but not started. Another report highlighted how wtATTR-CM can look like long-term athletic heart remodeling, and in that case definitive diagnosis required a heart biopsy even though the bone-tracer scan was strongly positive, after which tafamidis was started. [5] [7]

For patients and caregivers, these reports are most useful for understanding the range of real-life situations that can come up with wtATTR-CM, such as unclear valve testing in low-flow states, unexpected anatomic barriers during procedures, and the need for extra confirmation when the picture is confusing (for example, in highly trained athletes). They may matter now mainly as context for why some individuals undergo additional testing, monitoring, or highly tailored procedures, but they do not establish that a specific approach will work for others. What remains uncertain is how often these scenarios occur and which parts of the care plan made the biggest difference, because each report describes only 1 person. [3] [4] [5] [6] [7]